A group of inheritors takes charge with new ideas and new strategies.
India’s venerated $37 billion pharma industry is at the crossroads. The road to new drug discovery – after decades of disappointing results – is famously pot-holed and, with half-discoveries being touted as new drugs, appears to be leading nowhere; The road to money-spinners such as Para-IV exclusivity, generic-generics and branded generics is facing rapid speed-breakers of competition, commoditisation and price erosion. In the interim, domestic pharma majors went on the road to tactical M&As to foster growth. But the most promising road is the way to complex generics, specialty drugs and bio-similars. It is also the most arduous, requiring a decoction of cutting-edge science, speed and agility and outstanding selling prowess – neither of which is Indian pharma majors’ strength.
That calls for reassessing the ground realities and implementation of new strategies, fresh thinking and, most importantly, fresh blood. Just as the doctor ordered, the scions – some second generation and some third – of Indian pharma majors are readying to take on this onerous responsibility.
This is a watershed moment. If they succeed, India will still have a home-grown pharmaceutical industry. If they don’t, the domestic pharma landscape will be peppered with foreign-owned Indian pharma companies, a trend that has accelerated since the beginning of this decade.
Bu hikaye Business Today dergisinin May 21, 2017 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye Business Today dergisinin May 21, 2017 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
"Moving to cloud helped us grow❞
What was the problem you were grappling with?
She's Got Time
MORE WOMEN ARE BECOMING WATCH CONNOISSEURS, SEEKING OUT BOTH JEWELLED AND TECHNICAL WATCHES FOR THEIR STYLE AND CRAFTSMANSHIP
RISING STAR
PARUL GULATI IS a name that's been steadily gaining prominence in the Indian entertainment industry after she appeared on season 2 of Shark Tank in 2023. She has become a multifaceted personality who effortlessly transitions between acting and entrepreneurship.
Building on a Legacy
WHEN ZAHABIYA KHORAKIWALA stepped into her role as Managing Director of Wockhardt Hospitals over a decade ago, she confronted formidable challenges that have since turned into achievements.
LEADER IN INNOVATION
AS FEDEX'S PRESIDENT (Middle East, Indian subcontinent and Africa), Kami Viswanathan has a lot on her plate.
WAITING IN THE WINGS
Here are those who missed out as they have not yet completed a year in office; they'll be strong contenders in 2025
A DECENT PROPOSAL
IN TODAY'S WORLD OF TRYING TO CREATE AN EQUITABLE SPACE, BOTH MEN AND WOMEN CONTRIBUTE TO THEIR HOUSEHOLDS. WOMEN ARE ENCOURAGED TO HAVE THEIR OWN SAVINGS POOL AND INVESTMENT ROUTINE. GIVEN THIS, HOW SHOULD FUTURE BRIDES APPROACH FINANCIAL PLANNING?
Women and the STEM Bias
EMPOWERING WOMEN IN STEM WILL NOT ONLY BENEFIT INDIVIDUALS, BUT ALSO STRENGTHEN THE ENTIRE INDUSTRY, DRIVING INNOVATION AND PROGRESS.
ROCKET WOMEN
WOMEN IN INDIA ARE NOT ONLY VENTURING INTO SPACE BUT ARE ALSO STARTING TO SPEARHEAD THE COUNTRY'S EFFORTS IN THE GLOBAL SPACE RACE.
ONE STEP FORWARD
THE NUMBER OF WOMEN INDEPENDENT DIRECTORS IS GROWING STEADILY, BUT IT'S A LONG WAY FROM GENDER PARITY. MUCH MORE NEEDS TO BE DONE TO BREAK THE GLASS CEILING IN BOARDROOMS.